Voya Investment Management LLC Buys 40,500 Shares of MacroGenics, Inc. $MGNX

Voya Investment Management LLC raised its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 70.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,922 shares of the biopharmaceutical company’s stock after acquiring an additional 40,500 shares during the period. Voya Investment Management LLC owned about 0.16% of MacroGenics worth $124,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Strs Ohio bought a new position in MacroGenics during the 1st quarter valued at $263,000. Acadian Asset Management LLC increased its position in shares of MacroGenics by 78.8% during the 1st quarter. Acadian Asset Management LLC now owns 2,308,649 shares of the biopharmaceutical company’s stock valued at $2,923,000 after purchasing an additional 1,017,726 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of MacroGenics by 456,243.3% during the 1st quarter. Jones Financial Companies Lllp now owns 136,903 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 136,873 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of MacroGenics by 17.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 665,351 shares of the biopharmaceutical company’s stock valued at $845,000 after purchasing an additional 99,447 shares during the last quarter. Finally, Amundi purchased a new stake in shares of MacroGenics during the 1st quarter valued at $272,000. 96.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director William K. Heiden bought 50,500 shares of the business’s stock in a transaction on Tuesday, August 19th. The stock was acquired at an average price of $1.52 per share, for a total transaction of $76,760.00. Following the purchase, the director directly owned 61,500 shares in the company, valued at $93,480. This trade represents a 459.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 13.00% of the stock is currently owned by corporate insiders.

MacroGenics Stock Performance

Shares of MGNX opened at $1.70 on Thursday. MacroGenics, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $5.10. The business has a 50-day moving average of $1.66 and a 200 day moving average of $1.55. The firm has a market cap of $107.46 million, a P/E ratio of -2.98 and a beta of 1.61.

MacroGenics (NASDAQ:MGNX) last issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.02. MacroGenics had a negative return on equity of 40.24% and a negative net margin of 21.99%.The business had revenue of $22.24 million during the quarter, compared to the consensus estimate of $28.06 million. As a group, research analysts predict that MacroGenics, Inc. will post -1.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MGNX. Wall Street Zen lowered MacroGenics from a “hold” rating to a “sell” rating in a research report on Saturday, August 2nd. Leerink Partners decreased their target price on MacroGenics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, August 15th. Finally, Barclays began coverage on MacroGenics in a research report on Wednesday, September 17th. They set an “overweight” rating and a $3.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $3.60.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.